Research output per year
Research output per year
Personal profile
Professional Information
I am medical oncologist trained in Chile and formally trained again at the National Cancer Institute National Institutes of Health, Bethesda MD, obtaining my second oncology fellowship. Additionally, I have received direct lung cancer training from prestigious investigators such as Guiseppe Giacconne MD and medical Oncology mentorship by Antonio Fojo.
Research Interests
My main interest are immuno-oncology specific diseases such as lung cancer, renal cancer and melanoma and areas in medicine like Health policy and biostatistics.
I was editor of the Seminar in Oncology journal and currently I am one of the editors of Journal of Thoracic Oncology.
I have participated in more than 50 publications in indexed journals and have written several medical oncology books chapters.
I am also the Medical Director of the Cancer Center of Clínica Universidad de los Andes and the Medical Director of Bradford Hill clinical research center and have participated as principal investigator in more than 30 cancer clinical trials.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Medical Director, Bradford Hill Clinical Research Center.
1 Mar 2019 → …
Fingerprint
Dive into the research topics where Mauricio Burotto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Adjuvant therapy for renal cell carcinoma, finally a new standard?
Renner, A., Rojas, C., Walton-Diaz, A. & Burotto, M., 29 Sep 2022, In: Frontiers in Oncology. 12, 926661.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthélémy, P., Plimack, E. R., Porta, C., George, S., Powles, T., Donskov, F., Gurney, H., Kollmannsberger, C. K., Grimm, M. O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B. I., & 5 others, 1 Jun 2022, In: Cancer. 128, 11, p. 2085-2097 13 p.Research output: Contribution to journal › Article › peer-review
Open Access34 Scopus citations -
Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer
Valenzuela, G., Burotto, M., Marcelain, K. & González-Montero, J., 15 Sep 2022, In: World Journal of Gastrointestinal Oncology. 14, 9, p. 1654-1664 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Main mechanisms involved in major and minor side effects triggered by cisplatin-based therapy
Burotto, M., Cortés-Fuentes, I. A., Gonzalez-Montero, J. & Gormaz, J. G., 6 Oct 2022, Platinum-Based Chemotherapy: Clinical Uses, Efficacy and Side Effects. Nova Science Publishers, Inc., p. 79-100 22 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
Cardona, A. F., Ruiz-Patiño, A., Recondo, G., Martín, C., Raez, L., Samtani, S., Minata, J. N., Blaquier, J. B., Enrico, D., Burotto, M., Ordóñez-Reyes, C., Chamorro, D. F., Garcia-Robledo, J. E., Corrales, L., Zatarain-Barrón, Z. L., Más, L., Sotelo, C., Ricaurte, L., Santoyo, N., Cuello, M., & 19 others, Sep 2022, In: Clinical Lung Cancer. 23, 6, p. 522-531 10 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations
Press/Media
-
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
3/03/23
2 items of Media coverage
Press/Media
-
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
28/02/23
1 item of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Demonstrates Positive Results for Renal Cell Carcinoma
27/02/23
1 item of Media coverage
Press/Media
-
Nivolumab-plus cabozantinib improves outcomes in advanced renal cell carcinoma
23/02/23
2 items of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma
21/02/23
1 item of Media coverage
Press/Media